Durability Seen With Novartis, Roche SMA Therapies Heading For Market

 
• By John Davis

Novartis and Roche have announced additional interim clinical data as their candidate spinal muscular atrophy therapies near the marketplace.

Tyre
Investigational SMA therapies are looking durable as well as efficacious. • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies